If Trofinetide gets approved
If positive results are produced for all 4 phase two trials
if phase III trials have an end date within site
If Neuren choose to partner 2591 for 4 indications
If RoW deals are secured for Trof and 2591
If milestones are struck bringing in tens of millions
All in the next 12 months a share price anywhere between $30-$40 is not unreasonable IMO
Neuren will be a fully fledged profit generating company
Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference, page-9
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.56 |
Change
-0.010(0.06%) |
Mkt cap ! $1.988B | |||
| Open | High | Low | Value | Volume |
| $15.40 | $16.06 | $15.36 | $9.126M | 583.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 255 | $15.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.70 | 1442 | 2 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |